China Resources Pharmaceutical Group Past Earnings Performance
Past criteria checks 4/6
China Resources Pharmaceutical Group has been growing earnings at an average annual rate of 2.5%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 8% per year. China Resources Pharmaceutical Group's return on equity is 8.4%, and it has net margins of 1.6%.
Key information
2.5%
Earnings growth rate
2.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 8.0% |
| Return on equity | 8.4% |
| Net Margin | 1.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How China Resources Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 244,704 | 3,854 | 25,252 | 0 |
| 30 Sep 23 | 239,207 | 3,722 | 24,537 | 0 |
| 30 Jun 23 | 247,532 | 3,852 | 25,157 | 0 |
| 31 Mar 23 | 228,091 | 3,634 | 23,057 | 0 |
| 31 Dec 22 | 218,183 | 3,500 | 21,999 | 0 |
| 30 Sep 22 | 221,487 | 3,724 | 22,247 | 0 |
| 30 Jun 22 | 211,788 | 3,719 | 21,193 | 0 |
| 31 Mar 22 | 196,226 | 3,288 | 19,674 | 0 |
| 31 Dec 21 | 193,021 | 3,072 | 19,393 | 0 |
| 30 Sep 21 | 191,495 | 2,869 | 19,667 | 0 |
| 30 Jun 21 | 187,554 | 2,626 | 19,701 | 0 |
| 31 Mar 21 | 179,512 | 2,720 | 19,092 | 0 |
| 31 Dec 20 | 168,762 | 2,776 | 18,197 | 0 |
| 30 Sep 20 | 171,873 | 2,683 | 19,137 | 0 |
| 30 Jun 20 | 174,956 | 2,578 | 20,122 | 0 |
| 31 Mar 20 | 181,054 | 2,793 | 21,233 | 0 |
| 31 Dec 19 | 182,690 | 2,937 | 21,813 | 0 |
| 30 Sep 19 | 183,417 | 3,670 | 21,984 | 0 |
| 30 Jun 19 | 173,938 | 4,187 | 20,930 | 0 |
| 31 Mar 19 | 165,679 | 3,737 | 20,069 | 0 |
| 31 Dec 18 | 166,626 | 3,494 | 20,322 | 0 |
| 30 Sep 18 | 163,734 | 3,466 | 19,540 | 0 |
| 30 Jun 18 | 154,852 | 3,309 | 18,062 | 0 |
| 31 Mar 18 | 142,296 | 2,959 | 15,795 | 0 |
| 31 Dec 17 | 143,688 | 2,901 | 15,087 | 0 |
| 30 Sep 17 | 143,252 | 2,759 | 14,277 | 0 |
| 30 Jun 17 | 142,276 | 2,602 | 13,380 | 0 |
| 31 Mar 17 | 142,003 | 2,577 | 13,395 | 0 |
| 31 Dec 16 | 140,316 | 2,526 | 13,279 | 0 |
| 30 Sep 16 | 132,253 | 2,161 | 12,534 | 0 |
| 30 Jun 16 | 129,313 | 1,889 | 12,274 | 0 |
| 31 Mar 16 | 123,770 | 2,103 | 11,766 | 0 |
| 31 Dec 15 | 122,785 | 2,388 | 11,692 | 0 |
| 31 Dec 14 | 108,575 | 2,116 | 9,955 | 0 |
| 31 Dec 13 | 91,313 | 2,061 | 9,248 | 0 |
Quality Earnings: 640 has high quality earnings.
Growing Profit Margin: 640's current net profit margins (1.6%) are lower than last year (1.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 640's earnings have grown by 2.5% per year over the past 5 years.
Accelerating Growth: 640's earnings growth over the past year (10.1%) exceeds its 5-year average (2.5% per year).
Earnings vs Industry: 640 earnings growth over the past year (10.1%) exceeded the Pharmaceuticals industry 2.7%.
Return on Equity
High ROE: 640's Return on Equity (8.4%) is considered low.